M. Philco

Randomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients (pts) with advanced gastric cancer (AGC): Efficacy and safety results

Yoon‐Koo Kang, Won Ki Kang, Donghyun Shin et al. · Journal of Clinical Oncology · 2006 · 90 citations

Medicine, Oncology, Pharmacology +17

BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population

Nicholas C. Turner, Ashley E. Alarcon-Rozas, Anne Armstrong et al. · Annals of Oncology · 2019 · 89 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer

Henry Gómez, M. Philco, Patricia Pimentel et al. · Anti-Cancer Drugs · 2011 · 57 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study

Pieter W. Kamphuisen, A.Y.Y. Lee, Guy Meyer et al. · Journal of Thrombosis and Haemostasis · 2018 · 40 citations · Full text

Medicine, Hematology, Oncology +17

Abstract GS3-04: Double-blind placebo (PBO)-controlled randomized phase III trial evaluating first-line ipatasertib (IPAT) combined with paclitaxel (PAC) for <i>PIK3CA/AKT1/PTEN</i>-altered locally advanced unresectable or metastatic triple-negative breast cancer (aTNBC): primary results from IPATunity130 Cohort A

Rebecca Dent, Sung‐Bae Kim, Mafalda Oliveira et al. · Cancer Research · 2021 · 29 citations

Medicine, Oncology, Pharmacotherapy +17